Pharmacokinetics of the direct factor xa inhibitor edoxaban and digoxin administered alone and in combination

Journal of Cardiovascular Pharmacology

Volumn 60, Issue 4, 2012, Pages 335-341

  Mendell, Jeanne ^a   Noveck, Robert J ^b   Shi, Minggao ^a  

^a DAIICHI SANKYO INC   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

digoxin; druga drug interactions; edoxaban; P glycoprotein; pharmacokinetics

Indexed keywords

DIGOXIN; EDOXABAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHAPPED LIPS; CONTACT DERMATITIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ETHNICITY; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NORMAL HUMAN; OCCULT BLOOD; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SIDE EFFECT; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84867747564     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31826265b6.     Document Type: Article

References (29)

1. Camm AJ, Kirchhof P, Lip GY, et al; European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12:1360-1420.
2. Lip GY. Stroke in atrial fibrillation: epidemiology and thromboprophylaxis. J Thromb Haemost. 2011;9(suppl 1):344-351.
3. Fuster V, Rydén LE, Cannom DS, et al; American College of Cardiology Foundation/American Heart Association Task Force. ACCF/AHA/HRS focused updates incorporated into the 2011 ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:E269-E367.
4. Fuster V, Rydén LE, Cannom DS, et al; American College of Cardiology; American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006;8:651-745.
5. Gheorghiade M, Adams KF Jr, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation. 2004;109:2959-2964.
6. Lanoxin [package insert]. Research Triangle Park, NC: GlaxoSmith-Kline; 2009.
7. Sumner DJ, Russell AJ. Digoxin pharmacokinetics: multicompartmental analysis and its clinical implications. Br J Clin Pharmacol. 1976;3:221-229.
8. Kelman AW, Sumner DJ, Lonsdale M, et al. Comparative pharmacokinetics and pharmacodynamics of cardiac glycosides. Br J Clin Pharmacol. 1980;10:135-143.
9. Digoxin: serious drug interactions. Prescrire Int. 2010;19:68-70.
10. Furugohri T, Isobe K, Honda Y, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacologic profiles. J Thromb Haemost. 2008;6:1542-1549.
11. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010; 160:635-641.
12. Daiichi Sankyo Inc. Comparative investigation of low molecular weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). 2010. Available at: http://clinicaltrials.gov/ct2/ show/NCT00986154. Accessed October 30, 2010.
13. Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50: 743-753.
14. Bathala M, Masumoto H, Oguma T, et al. Biotransformation of edoxaban after oral administration to humans. Poster presented at: Pharmaceutical Sciences World Congress; November 17, 2010; New Orleans, LA.
15. Masumoto H, Yoshigae Y, Watanabe K, et al. In vitro metabolism of edoxaban and the enzymes involved in the oxidative metabolism of edoxaban. Poster presented at: Pharmaceutical Sciences World Congress; November 17, 2010; New Orleans, LA.
16. Sakaeda T, Nakamura T, Okumura K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull. 2002;25:1391-1400.
17. Al-Shawi MK, Omote H. The remarkable transport mechanism of P-glycoprotein: a multidrug transporter. J Bioenerg Biomembr. 2005; 37:489-496.
18. Eberl S, Renner B, Neubert A, et al. Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. Clin Pharmacokinet. 2007;46:1039-1049.
19. Oswald S, Terhaag B, Siegmund W. In vivo probes of drug transport: commonly used probe drugs to assess function of intestinal P-glycoprotein (ABCB1) in humans. Handb Exp Pharmacol. 2011;201:403-447.
20. Bauer KA. Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. J Thromb Haemost. 2011;9(suppl 1): 12-19.
21. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 2003;42:59-98.
22. Mizuno N, Niwa T, Yotsumoto Y, et al. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev. 2003;55: 425-461.
23. Iisalo E. Clinical pharmacokinetics of digoxin. Clin Pharmacokinet. 1977;2:1-16.
24. Barclay M, Begg E. The practice of digoxin therapeutic drug monitoring. N Z Med J. 2003;116:U704.
25. Lindenfeld J, Albert NM, Boehmer JP, et al; Heart Failure Society of America. HFSA Comprehensive heart failure practice guideline. J Card Fail. 2010;16:E1-E194.
26. Salazar DE, Mendell J, Kastrissios H, et al. Modeling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost. 2012;107:925-936.
27. Marchetti S, Mazzanti R, Beijnen JH, et al. Concise review: clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist. 2007; 12:927-941.
28. Giacomini KM, Huang SM, Tweedie DJ, et al; International Transporter Consortium. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215-236.
29. Mendell J, Zahir H, Ridout G, et al. Drug-drug interaction studies of cardiovascular drugs (quinidine, digoxin, amiodarone, verapamil, and atorvastatin) involving P-glycoprotein (P-gp), an efflux transporter, on the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban, an oral factor Xa inhibitor. Poster presented at: 60th Annual American College of Cardiology Scientific Session and Expo, April 2-5, 2011, New Orleans, LA.